Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)
Satoshi Hattori, Masami Tanaka, Kazutaka Shiomi, Hirofumi Ochi et al.
Journal
Multiple Sclerosis Journal
Topics
Multiple Sclerosis Research Studies
article
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)
University of Miyazaki (JP), Fukushima Medical University (JP), Tokai University (JP), Kyushu University (JP), St. Marianna University School of Medicine (JP), Wakayama Medical University (JP), Kagawa University (JP), Keio University (JP), Juntendo University (JP), Kyoto College of Medical Science (JP), National Hospital Organization Hokkaido Medical Center (JP), Nagoya Ekisaikai Hospital (JP), National Hospital Organization (JP), Utano Hospital (JP), Gifu University (JP), Ehime University (JP), Tohoku Medical and Pharmaceutical University (JP), The University of Osaka (JP)